

Structure and stability of the *Human respiratory syncytial virus* M₂₋₁ RNA-binding core domain reveals a compact and cooperative folding unit

Ivana G. Molina,^a Inokentij Josts,^b Yasser Almeida Hernandez,^b Sebastian Esperante,^a Mariano Salgueiro,^a Maria M. Garcia Alai,^c Gonzalo de Prat-Gay^{a,*} and Henning Tidow^{b,§}

Received 27 October 2017

Accepted 4 December 2017

Edited by M. W. Bowler, European Molecular Biology Laboratory, France

‡ These authors contributed equally.

§ Joint corresponding authors and made equal contributions.

Keywords: viral proteins; crystal structure; small-angle X-ray scattering; protein folding; *Human syncytial respiratory virus*.

PDB references: HRSV M₂₋₁ core, 5nkk; 5noh

Supporting information: this article has supporting information at journals.iucr.org/f


^aProtein Structure–Function and Engineering Laboratory, Fundación Instituto Leloir and IIBBA–CONICET, Avenida Patricias Argentinas 435, C1405BWE Buenos Aires, Argentina, ^bThe Hamburg Centre for Ultrafast Imaging and Department of Chemistry, Institute for Biochemistry and Molecular Biology, University of Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany, and ^cEuropean Molecular Biology Laboratory (EMBL), Hamburg Unit, Notkestrasse 85, 22607 Hamburg, Germany. *Correspondence e-mail: gpg@leloir.org.ar, tidow@chemie.uni-hamburg.de

Human syncytial respiratory virus is a nonsegmented negative-strand RNA virus with serious implications for respiratory disease in infants, and has recently been reclassified into a new family, *Pneumoviridae*. One of the main reasons for this classification is the unique presence of a transcriptional antiterminator, called M₂₋₁. The puzzling mechanism of action of M₂₋₁, which is a rarity among antiterminators in viruses and is part of the RNA polymerase complex, relies on dissecting the structure and function of this multidomain tetramer. The RNA-binding activity is located in a monomeric globular ‘core’ domain, a high-resolution crystal structure of which is now presented. The structure reveals a compact domain which is superimposable on the full-length M₂₋₁ tetramer, with additional electron density for the C-terminal tail that was not observed in the previous models. Moreover, its folding stability was determined through chemical denaturation, which shows that the secondary and tertiary structure unfold concomitantly, which is indicative of a two-state equilibrium. These results constitute a further step in the understanding of this unique RNA-binding domain, for which there is no sequence or structural counterpart outside this virus family, in addition to its implications in transcription regulation and its likeliness as an antiviral target.

1. Introduction

Human respiratory syncytial virus (HRSV) is a nonsegmented negative-strand RNA virus of the recently reclassified *Pneumoviridae* family (Afonso *et al.*, 2016) and is a major cause of lower respiratory tract infections in children, the elderly and the immunocompromised, including acute bronchiolitis and pneumonia (Reed *et al.*, 1997; Lay *et al.*, 2013; Amarasinghe *et al.*, 2017). HRSV is an enveloped virus; its genome consists of a 15.2 kb single-stranded nonsegmented negative-sense RNA that contains ten genes which encode 11 proteins. Four of them are part of the nucleocapsid: the nucleocapsid protein N, the polymerase cofactor phosphoprotein P, the transcription antitermination factor M₂₋₁ and the viral polymerase L. The virus also encodes two non-structural proteins (NS1 and NS2) and three transmembrane proteins: the fusion F protein, the small hydrophobic SH protein and the G glycoprotein.

The viral polymerase complex is responsible for carrying out genome replication, transcription and post-transcriptional



OPEN ACCESS

modifications of mRNAs and consists of genomic RNA tightly bound to the nucleocapsid N protein and the P, L and M₂₋₁ proteins (Collins *et al.*, 2001). The M₂₋₁ transcription anti-terminator factor is a basic protein of 194 amino acids that exists as a stable tetramer in solution (Tran *et al.*, 2009; Tanner *et al.*, 2014; Esperante *et al.*, 2011) and is essential for the complete sequential transcription of mRNAs in HRSV (Collins *et al.*, 1995, 1996; Yu *et al.*, 1995; Hardy & Wertz, 1998). It harbours four distinct regions: an N-terminal zinc-binding domain (ZBD; residues 7–25), an α -helical tetramerization domain (TD; residues 32–49), an RNA-binding core domain (RBD; residues 69–172) and a C-terminal unstructured region (residues 173–194). A crystal structure of the tetrameric M₂₋₁ assembly (Tanner *et al.*, 2014) and an NMR structure of the monomeric M₂₋₁ RBD (residues 58–177; Blondot *et al.*, 2012) have been determined. M₂₋₁ oligomerization is primarily driven by a central tetramerization α -helix and is also stabilized by contacts between the zinc-binding domain and the core of an adjacent monomer (Tanner *et al.*, 2014; Fig. 1). The removal of zinc leads to tetramer dissociation into a monomeric apo M₂₋₁ species in solution. Thus, the integrity of the ZBD seems to be critical for the tetrameric assembly and for protein function (Esperante *et al.*, 2013).

The crystallographic structure of the closely related *Human metapneumovirus* (HMPV) M₂₋₁ protein revealed that the ZBD interacts with the tetramerization helix through a hydrophobic interface. The core domain interacts with the ZBD, and the tetramerization and core domains of adjacent protomers, mostly through polar contacts (Leyrat *et al.*, 2014). Interestingly, each protomer exists in an equilibrium between an open and a closed conformation. RNA binding induces the closed state, while the addition of subdenaturing concentrations of guanidinium chloride (GdmCl) induces an open state, consistent with the polar nature of the interactions between

Table 1
Data-collection and refinement statistics.

Values in parentheses are for the highest resolution shell.

	HRSV M ₂₋₁ core (PDB entry 5noh)	HRSV M ₂₋₁ core (PDB entry 5nkk)
Data collection		
Space group	<i>P</i> 2	<i>P</i> 3 ₂ 21
<i>a</i> , <i>b</i> , <i>c</i> (Å)	37.95, 69.24, 46.60	91.95, 91.95, 97.80
α , β , γ (°)	90, 90.05, 90	90, 90, 120
Resolution (Å)	46.60–1.80 (1.86–1.80)	41.67–2.00 (2.07–2.00)
<i>R</i> _{merge}	0.050 (0.518)	0.043 (0.570)
$\langle I/\sigma(I) \rangle$	12.1 (1.70)	10.0 (1.29)
CC _{1/2}	0.99 (0.66)	0.99 (0.29)
Completeness (%)	94.8 (69.4)	99.98 (100)
Multiplicity	3.1 (2.4)	2.0 (2.0)
Refinement		
Resolution (Å)	1.8	2.0
No. of reflections	21206 (1591)	32735 (3196)
<i>R</i> _{work} / <i>R</i> _{free}	0.171/0.210	0.189/0.228
No. of atoms		
Total	1794	1857
Protein	1618	1668
Water	176	189
<i>B</i> factors (Å ²)		
Protein	37.9	42.1
Water	45.3	50.4
R.m.s. deviations		
Bond lengths (Å)	0.007	0.003
Bond angles (°)	0.83	0.54

the core domain and the rest of the molecule (Leyrat *et al.*, 2014).

Given the relevance and uniqueness of this viral transcription antiterminator, we set out to investigate its RNA-binding domain (residues 73–194) using X-ray crystallography and folding thermodynamics. The structure of the monomeric domain is superimposable with that of the tetramer, but uncovers additional structured residues at the C-terminus that have not been observed previously. The folding studies reveal




Figure 1
Domain interactions in tetrameric full-length HRSV M₂₋₁. One monomer within the tetrameric full-length protein is coloured; the other three monomers are displayed in grey tones. The tetramerization domain is coloured yellow, the zinc-binding domain is in orange, the Zn²⁺ ion is in magenta and the RBD core domain is in cyan (PDB entry 4c3b).

that although the RBD shows inter-monomer contacts and contacts the ZBD from neighbouring monomers in the tetramer, these do not influence its structure or stability.

2. Materials and methods

2.1. Protein expression and purification

The HRSV M_{2-1} protein from strain A was recombinantly expressed in bacteria and purified as described previously (Esperante *et al.*, 2013). The highly purified full-length M_{2-1} tetramer was then subjected to limited proteolysis using chymotrypsin from bovine pancreas (Sigma–Aldrich) at a 1:60(*w:w*) protein:chymotrypsin ratio in 50 mM Tris–HCl pH 8.0 for 90 min at 28°C. The reaction was stopped by adding 1 mM phenylmethylsulfonyl fluoride (PMSF) and subsequently subjected to size-exclusion chromatography on a Superdex 75 column in 20 mM Tris–HCl pH 7.0, 300 mM

NaCl. The resulting RBD protein after proteolysis comprises amino acids Ala73–Tyr194. Its molecular weight of 13.6 kDa was confirmed by MALDI–TOF mass spectrometry (Bruker, Daltonics, Billerica, Massachusetts, USA) and the protein elutes as a monomeric peak from size-exclusion chromatography (Supplementary Fig. S2). The protein concentration was determined spectrophotometrically using an extinction coefficient (ϵ_{280}) of 4470 $M^{-1} \text{ cm}^{-1}$.

2.2. Folding and stability

Equilibrium denaturation experiments were performed by incubating a 5 μM protein sample with increasing concentrations of guanidinium chloride (GdmCl) in 20 mM Tris–HCl pH 7.0. The samples were incubated for 16 h at 20°C prior to measurements. CD spectra were recorded on a Jasco 815 spectropolarimeter. The CD data were fitted to a two-state model as described previously (Pretel *et al.*, 2013).




Figure 2 Overall structure of the HRSV M_{2-1} RBD. (a) Cartoon representation of the HRSV M_{2-1} RBD rainbow-coloured from the N-terminus (blue) to the C-terminus (red). (b) Superposition of the HRSV M_{2-1} RBD crystal structure (blue) with the NMR structure (orange) and the crystal structure of the corresponding domain in the tetrameric assembly (grey). (c) Composite OMIT map of the C-terminal tail (residues 178–185) in the HRSV M_{2-1} RBD structure ($P3_221$ crystal form) contoured at 1.5σ . The colour code and orientation are as in (a), except for the C-terminal tail, which is displayed according to atom type. (d) Close-up of the C-terminal tail with contacting residues, waters and bond lengths.

Fluorescence spectroscopy was carried out using a Horiba Fluoromax-4 spectrofluorometer with excitation at 275 nm. Intensity at 310 nm, corresponding to tyrosine fluorescence, was plotted as a function of the denaturant concentration. All measurements were performed at 20°C.

2.3. Crystallization and data collection

Initial M_{2-1} RBD crystallization conditions were identified using the vapour-diffusion technique in sitting drops in a high-throughput crystallization screen. The most promising hits were then optimized by mixing 1 μ l M_{2-1} RBD solution (11 mg ml⁻¹) with 1 μ l reservoir solution and equilibrating against reservoir solution consisting of either condition 1 (2.1 M DL-malic acid pH 7) or condition 2 (2.4 M sodium malonate pH 7) (both from the JCSG *plus* screen) at 293 K. The crystals belonged to space groups $P2$ and $P3_221$, respectively, and both diffracted to better than 2 Å resolution. Crystals appeared after 1 d and grew to maximum dimensions

of 0.6 × 0.8 × 1.0 mm within one week (Supplementary Fig. S1). Crystals were mounted and flash-cooled in liquid nitrogen with cryoprotection (by the addition of 20% glycerol to the crystallization solution). Diffraction data were collected to a resolution limit of 1.8–2.0 Å. Full data sets with an interval of 0.1° were collected for both crystal forms on the P14 beamline at EMBL/DESY, Hamburg, Germany. All data sets were processed with *XDS* (Kabsch, 2010) and merged with *AIMLESS* (Evans, 2006). A summary of the data statistics is given in Table 1.

2.4. Structure determination, refinement and analysis

The structures were solved by molecular replacement with *Phaser* (McCoy *et al.*, 2007) using PDB entry 4c3b (Tanner *et al.*, 2014) as the search model. Subsequent rounds of manual building using *Coot* (Emsley & Cowtan, 2004) and refinement using *phenix.refine* (Afonine *et al.*, 2012) allowed the model building of a short C-terminal extension of the M_{2-1} RBD




Figure 3 Structural comparison with tetrameric full-length HRSV M_{2-1} and HMPV M_{2-1} . (a) Superposition of the HRSV M_{2-1} RBD (blue) with full-length HRSV M_{2-1} . (b) Superposition of the HRSV M_{2-1} RBD (blue) with full-length HMPV M_{2-1} . Within the full-length proteins, the tetramerization domains are coloured yellow, zinc-binding domains orange and the RBD core domains grey. Zn^{2+} ions are displayed as magenta spheres. The C-terminal tail (residues 178–185) in the HRSV M_{2-1} RBD structure that is not present in the tetrameric crystal structure is displayed as sticks and coloured cyan.

(residues 73–194) in space group $P3_221$. The final models yielded crystallographic R factors of 17 and 19% and free R factors of 21 and 23% for the crystals in space groups $P2$ and $P3_221$, respectively (see Table 1 for details). The models were validated using *MolProbity* (Chen *et al.*, 2010). Evaluation of the Ramachandran plot showed all residues to be in allowed regions (97–99% in favoured regions). All figures were prepared using *PyMOL* (DeLano, 2002). The data have been deposited in the Protein Data Bank with PDB codes 5noh ($P2$) and 5nkx ($P3_221$).

2.5. Small-angle X-ray scattering (SAXS)

SAXS data were collected on the P12 beamline at EMBL/DESY, Hamburg following standard procedures. Repetitive data collection from the same sample was performed and no radiation damage was detected. Samples of M_{2-1} RBD (residues Ala73–Tyr194) solution were prepared in the concentration range 4.5–9.0 mg ml⁻¹ in a buffer consisting of 20 mM Tris–HCl pH 7, 300 mM NaCl. All SAXS data were analyzed using the *ATSAS* package (Franke *et al.*, 2017). Raw data were processed using *PRIMUS* (Konarev *et al.*, 2003). The radius of gyration (R_g) was evaluated using the Guinier approximation

[$I(s) = I(0)\exp(-s^2R_g^2/3)$ for $sR_g < 1.3$] and also from the entire scattering curve with *GNOM* (Svergun, 1992); the latter also provided the distance distribution function $p(r)$ and the maximum dimension D_{max} . The masses of the solutes were evaluated by comparison of the forward scattering intensity with that from a BSA reference solution (66 kDa). Low-resolution SAXS models were obtained using the *ab initio* simulated-annealing (SA) program *DAMMIF* (Franke & Svergun, 2009), which generates models consisting of dummy atoms to fit the experimental data.

3. Results and discussion

The HRSV M_{2-1} RBD domain crystallized in two different space groups (Table 1) and the structure could be determined to 2.0 Å resolution. The structure consists of six α -helices connected by short loops (Fig. 2*a*). The structures from both crystal forms are virtually identical in the core region (residues 58–177), with a root-mean-square deviation (r.m.s.d. on C^α atoms) of 0.3 Å. They are also very similar to the core domains observed in the crystal structure of full-length tetrameric HRSV M_{2-1} (Tanner *et al.*, 2014; r.m.s.d. of 0.7 Å) and in the NMR structure (Blondot *et al.*, 2012; r.m.s.d. of 1.39 Å)




Figure 4 Small-angle X-ray scattering (SAXS) analysis of the M_{2-1} RBD. (a) Raw scattering profile of the HRSV M_{2-1} RBD with the Guinier region shown in the inset. (b) Kratky plot suggesting the presence of a folded core with a flexible tail. (c) Distance distribution plot. (d) *Ab initio* shape reconstruction (grey) superimposed on the crystal structure of the HRSV M_{2-1} RBD (PDB entry 5noh; blue). The N- and C-termini of the protein are highlighted in green and red, respectively.

(Fig. 2*b*). A notable exception is the C-terminal region (residues 178–185), which could be clearly modelled in one monomer in the *P321* crystal form. In the tetrameric HRSV M_{2-1} crystal structure this region was disordered and thus not visible (Tanner *et al.*, 2014). In our *P321* core-domain structure it is located in a cleft between helices H3 and H6 and occupies a position that would interfere with the zinc-binding domain (ZBD) of another monomer in the tetrameric assembly (Figs. 2*c* and 3). We have shown that removing the zinc leads to a monomeric ‘apo’ form, which otherwise contains the same secondary structure as the tetrameric species, indicating that the ZBD modulates M_{2-1} oligomerization. In fact, this tetramer–monomer transition is increased at pH 5.5, strongly suggesting that the ZBD acts as a pH sensor that modulates quaternary structure (Esperante *et al.*, 2013).

The HRSV M_{2-1} RBD crystallized with two molecules in the asymmetric unit. The elution profile from size-exclusion

chromatography indicates that the HRSV M_{2-1} RBD exists as a monomer in solution (Supplementary Fig. S2). However, in order to confirm the oligomeric state of the HRSV M_{2-1} RBD in solution at the high concentration used in the crystallization conditions, we performed small-angle X-ray scattering (SAXS) experiments. Model-free analysis of the SAXS data yielded an R_g of 20.3 Å from the Guinier plot (Fig. 4*a*) and a Porod volume of 26.4 nm³, indicating a molecular weight of 15 kDa. The pair distance distribution function indicates a globular particle with a tail, with maximum dimensions (D_{max}) of 8 nm (Fig. 4*c*). The *ab initio* model of RBD obtained using DAMMIF is comparable to that of the crystal structure monomer (Fig. 4*d*). The C-terminal tail observed in our *P321* model could be extended in solution and would therefore explain the lack of globularity in our SAXS model. Electron density for this region has not been observed in previous crystal structures.

The RNA-binding core domain appears to be a compact and cooperative folding unit in the crystal structure reported here and the previous NMR structure of a similar fragment (Tanner *et al.*, 2014). However, there are several intermonomer contacts in the tetramer, and other contacts connecting with other regions of the protein, which raises the questions of whether the domain is stabilized by such interactions and to what extent the domain is compact and stable in solution. We carried out equilibrium unfolding experiments using guanidine chloride, and followed the secondary-structure transition by monitoring changes in circular dichroism (CD) in the far-UV region. The mostly α -helical spectrum with the characteristic minima at 208 and 222 nm is gradually lost upon an increase in denaturant, indicating complete unfolding of the protein (M_{2-1} RBD; Fig. 5*a*). The molar ellipticity change at 222 nm shows a highly cooperative transition suggestive of a two-state transition (Fig. 5*b*). Since there are no tryptophan residues, we used tyrosine intrinsic fluorescence as a probe for tertiary structure, which produces a transition superimposable with the secondary structure, which is a strong indication of a two-state unfolding process (Fig. 5*b*). For a quantitative analysis of the thermodynamic stability, we fitted the ellipticity data to a two-state model (Pretel *et al.*, 2013) and obtained an unfolding free-energy change (ΔG_{H_2O}) of 5.21 ± 0.92 kcal mol⁻¹ and an m value of 2.28 ± 0.38 kcal mol⁻¹ M⁻¹; the latter matches that expected for a globular two-state folder of this size (Myers *et al.*, 1995).

We have previously shown that zinc removal dissociates the tetramer, and the ‘apo’ M_{2-1} monomer obtained showed a secondary structure surprisingly identical to that of the tetramer (Esperante *et al.*, 2013). The unfolding transition of the M_{2-1} RBD is superimposable on that of the apo M_{2-1} monomer (Fig. 5*b*, inset), with a ΔG_{H_2O} of 5.89 ± 0.33 kcal mol⁻¹ and an m value of 2.62 ± 0.15 kcal mol⁻¹ M⁻¹, which is in excellent agreement with the stability and m value of the monomeric RBD, confirming that the isolated monomeric RNA-binding domain is a folding unit that is independent of the rest of the molecule either as a tetramer or an apo monomer. These results indicate that the rest of the polypeptide (residues 1–72) is disordered when the zinc is removed




Figure 5 Unfolding transitions of the M_{2-1} RBD. (a) Far-UV CD spectra of the M_{2-1} RBD at increasing concentrations of GdmCl from 0 to 5 M, as indicated by the arrow. (b) RBD equilibrium unfolding transition followed by the molar ellipticity at 220 nm (empty circles) and tyrosine fluorescence at 310 nm (filled circles). Ellipticity data were fitted to a two-state unfolding model (see §2). Inset: comparison of GdmCl equilibrium unfolding of apo M_{2-1} (empty circles; Esperante *et al.*, 2011) with the M_{2-1} RBD (filled circles) monitored by the changes in molar ellipticity at 220 nm. Experiments were carried out at pH 7.0 (see §2).

and the tetramer dissociates, or at least there is no cooperative compact structure.

The fact that the M_{2-1} RBD is a stable and compact domain showing two-state cooperative unfolding, with identical thermodynamic stability to the apo M_{2-1} monomer, shows that the region that is missing in the isolated domain (residues 1–72) does not partake in any persistent structure, is not connected to the M_{2-1} RBD and forms the tetrameric interface only when the zinc-binding motif is intact (Esperante *et al.*, 2013; Fig. 1). Although only one highly symmetric structure was observed in the crystal structure of the HRSV M_{2-1} tetramer (Tanner *et al.*, 2014), the homologue from *Human metapneumovirus* (HMPV) showed open and closed conformations in which different RBDs move away from the tetrameric arrangement, and this conformational change was proposed to be the result of RNA binding (Leyrat *et al.*, 2014). The structure of the HMPV RBD does not change in the open or closed conformations, suggesting that there must be a flexible regulatory region which moves the RBD back and forth. In this picture, contacts of the RBD with other RBDs or other regions (*i.e.* the zinc-binding motif) must be regulatory, with no effect on RBD conformation or stability. In the HRSV tetramer, three of the chains show a lack of electron density between the tetramerization domain and the RBD (Tanner *et al.*, 2014), coincident with what could constitute a flexible hinge region that may modulate the open–closed transition. In the HMPV tetramer structure the same region also lacks electron density in the linker region between the TD and RBD, indicating high flexibility (as reflected by very high *B* factors for adjacent residues). On the other hand, the crystal structures presented here strongly suggest that the carboxy-terminal region of the protein would be unstructured in the closed conformation present in the RNA-free tetramer and folds upon the helical cleft corresponding to the ZBD-binding region in the RBD. In any case, the structures of both complexes with RNA plus mechanistic studies of the interaction with RNA are required for a complete picture of this puzzling transcription antiterminator activity that governs the relative viral protein levels, as determined by the action of the M_{2-1} tetramer unique to these two viruses within the pneumovirus family.

Acknowledgements

We thank members of the Tidow and Prat-Gay laboratories for valuable discussions and Katharina Veith for technical assistance. We are very grateful to the staff of beamlines P12, P13 and P14 at EMBL/DESY, Hamburg. The Sample Preparation and Characterization (SPC) Facility of EMBL Hamburg is acknowledged for support in crystallization screening. Author contributions are as follows: conceptualization, GP-G and HT; investigation, IGM, IJ, YAH and SE; analysis and interpretation, IGM, IJ, YAH, SE, MS, MGA, GP-G and HT; manuscript writing, IGM, IJ, GP-G and HT; funding acquisition and supervision, GP-G and HT. We declare no competing financial interests.

Funding information

Support from the European Community Research Infrastructure Action under the FP7 is acknowledged for access to EMBL/DESY, Hamburg. IJ, YAH and HT are supported by the excellence cluster ‘The Hamburg Center for Ultrafast Imaging – Structure, Dynamics and Control of Matter at the Atomic Scale’ of the German Research Foundation (DFG). In addition, HT is grateful for support by an Emmy Noether Fellowship from the German Research Foundation (DFG). IGM is grateful for the financial support provided by Boehringer Ingelheim Fonds to travel to Hamburg, Germany to perform parts of these experiments.

References

- Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012). *Acta Cryst.* **D68**, 352–367.
- Afonso, C. L. *et al.* (2016). *Arch. Virol.* **161**, 2351–2360.
- Amarasinghe, G. K. *et al.* (2017). *Arch. Virol.* **162**, 2493–2504.
- Blondot, M.-L., Dubosclard, V., Fix, J., Lassoued, S., Aumont-Nicaise, M., Bontems, F., Eléouët, J.-F. & Sizun, C. (2012). *PLoS Pathog.* **8**, e1002734.
- Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). *Acta Cryst.* **D66**, 12–21.
- Collins, P. L., Chanock, R. M. & Murphy, B. R. (2001). *Fields Virology*, 4th ed., edited by D. M. Knipe & P. M. Howley, pp. 1443–1486. Philadelphia: Lippincott, Williams & Wilkins.
- Collins, P. L., Hill, M. G., Camargo, E., Grosfeld, H., Chanock, R. M. & Murphy, B. R. (1995). *Proc. Natl Acad. Sci. USA*, **92**, 11563–11567.
- Collins, P. L., Hill, M. G., Cristina, J. & Grosfeld, H. (1996). *Proc. Natl Acad. Sci. USA*, **93**, 81–85.
- DeLano, W. L. (2002). *PyMOL*. <http://www.pymol.org>.
- Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.
- Esperante, S. A., Chemes, L. B., Sánchez, I. E. & de Prat-Gay, G. (2011). *Biochemistry*, **50**, 8529–8539.
- Esperante, S. A., Noval, M. G., Altieri, T. A., de Oliveira, G. A., Silva, J. L. & de Prat-Gay, G. (2013). *Biochemistry*, **52**, 6779–6789.
- Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
- Franke, D., Petoukhov, M. V., Konarev, P. V., Panjkovich, A., Tuukkanen, A., Mertens, H. D. T., Kikhney, A. G., Hajizadeh, N. R., Franklin, J. M., Jeffries, C. M. & Svergun, D. I. (2017). *J. Appl. Cryst.* **50**, 1212–1225.
- Franke, D. & Svergun, D. I. (2009). *J. Appl. Cryst.* **42**, 342–346.
- Hardy, R. W. & Wertz, G. W. (1998). *J. Virol.* **72**, 520–526.
- Kabsch, W. (2010). *Acta Cryst.* **D66**, 125–132.
- Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H. J. & Svergun, D. I. (2003). *J. Appl. Cryst.* **36**, 1277–1282.
- Lay, M. K., González, P. A., León, M. A., Céspedes, P. F., Bueno, S. M., Riedel, C. A. & Kalergis, A. M. (2013). *Microbes Infect.* **15**, 230–242.
- Leyrat, C., Renner, M., Harlos, K., Huiskonen, J. T. & Grimes, J. M. (2014). *Elife*, **3**, e02674.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Myers, J. K., Pace, C. N. & Scholtz, J. M. (1995). *Protein Sci.* **4**, 2138–2148.
- Pretel, E., Camporeale, G. & de Prat-Gay, G. (2013). *PLoS One*, **8**, e74338.
- Reed, G., Jewett, P. H., Thompson, J., Tollefson, S. & Wright, P. F. (1997). *J. Infect. Dis.* **175**, 807–813.
- Svergun, D. I. (1992). *J. Appl. Cryst.* **25**, 495–503.

Tanner, S. J., Ariza, A., Richard, C.-A., Kyle, H. F., Dods, R. L., Blondot, M.-L., Wu, W., Trincão, J., Trinh, C. H., Hiscox, J. A., Carroll, M. W., Silman, N. J., Eléouët, J.-F., Edwards, T. A. & Barr, J. N. (2014). *Proc. Natl Acad. Sci. USA*, **111**, 1580–1585.

Tran, T.-L., Castagné, N., Dubosclard, V., Noinville, S., Koch, E., Moudjou, M., Henry, C., Bernard, J., Yeo, R. P. & Eléouët, J.-F. (2009). *J. Virol.* **83**, 6363–6374.

Yu, Q., Hardy, R. W. & Wertz, G. W. (1995). *J. Virol.* **69**, 2412–2419.